Publications by authors named "Michael Hurwitz"

Claim this Profile
S
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
Noam Savion-Gaiger, Bryden Considine, Nitzan Hasson, Melanie Nelson, Veronica Chiang, Michael E Hurwitz

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.
Noam Savion Gaiger, Michael E Hurwitz, Navid Hafez, Harriet M Kluger, Kevan C Herold

Front Endocrinol (Lausanne)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, Jacqueline E Mann, Madeline Candelas Torres, Michael Hurwitz

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.
Hannah D McManus, Jessica B Long, Sarah J Westvold, Michael S Leapman, Michael E Hurwitz

Clin Genitourin Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede, Michael E Hurwitz

Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors.
Philippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, Irvin Yi, Baylee Bakkila, Michael Hurwitz

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.
David A Schoenfeld, Dijana Djureinovic, David G Su, Lin Zhang, Benjamin Y Lu, Michael Hurwitz

JCI Insight· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.
Rebecca Forman, Jessica B Long, Sarah J Westvold, Khushi Agnish, Hannah D Mcmanus, Michael E Hurwitz

JNCI Cancer Spectr· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.
Oscar Perales, Lucia Jilaveanu, Adebowale Adeniran, David G Su, Michael Hurwitz

Cancer Immunol Immunother· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher

Cancer Discov· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.
Ayesha Butt, Jana Christian, Anna Kress, Benjamin Y Lu, Michael E Hurwitz

J Cancer Educ· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Michael Hurwitz

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Michael Hurwitz

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Michael Hurwitz

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Syed N Rahman, Jessica B Long, Sarah J Westvold, Michael S Leapman, Lisa P Spees, Michael E Hurwitz

JAMA Netw Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Michael Hurwitz

Mol Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics.
Soum D Lokeshwar, Ankur U Choksi, Daniel Haltstuch, Syed N Rahman, Benjamin H Press, Michael E Hurwitz

World J Urol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
David A Schoenfeld, Myrto Moutafi, Sandra Martinez, Dijana Djureinovic, Ross D Merkin, Michael Hurwitz

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
Ryan D Chow, Jessica B Long, Sirad Hassan, Stephanie B Wheeler, Lisa P Spees, Michael E Hurwitz

JNCI Cancer Spectr· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Nazli Dizman, Matthew Austin, Bryden Considine, Shlomit Jessel, David Schoenfeld, Michael Hurwitz

Clin Genitourin Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Harriet Kluger, J Carl Barrett, Justin F Gainor, Omid Hamid, Michael Hurwitz

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Michael Hurwitz

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure.
Rihao Qu, Yuval Kluger, Junchen Yang, Jun Zhao, David A Hafler, Michael Hurwitz

Mol Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.
David A Schoenfeld, Ross D Merkin, Myrto Moutafi, Sandra Martinez, Adebowale Adeniran, Michael Hurwitz

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
Robert S Seitz, Michael E Hurwitz, Tyler J Nielsen, Daniel B Bailey, Matthew G Varga

J Transl Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis